A Survey of Midazolam in People With Status Epilepticus

Recruiting now

Conditions studied: Epilepsy

In brief

This study is a survey in Japan of midazolam oromucosal solution used to treat people with status epilepticus. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from midazolam oromucosal solution and to check if midazolam oromucosal solution improves symptoms of status epilepticus. During the study, participants with status epilepticus will take midazolam oromucosal solution according to their clinic's standard practice. The study doctors will check for side effects from midazolam for 6 months.

Key facts

Study ID

NCT05313308

Run by

Clinigen K.K.

People needed

50

Starts

2021-06-01

Expected to finish

2028-08-31

Last updated by the study team

2026-05-18

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with non-convulsive status epilepticus
• Participants treated with study drug outside the medical institution
• Participants receiving an additional dose of study drug
• Exclusion Criteria Participants have any contraindication to midazolam.

Where it is running

• Clinigen selected site — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.